Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Ryan S. Jackson et al.|Clinical Cancer Research|2020Cited by 368
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell CarcinomasTenny Mudianto, Ravindra Uppaluri, Katie M. Campbell et al.|Clinical Cancer Research|2021Cited by 40
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Katie M. Campbell et al.|Clinical Cancer Research|2021Cited by 14
Lymphatic constraint of germinal centers optimizes protective antibody responsesTenny Mudianto, Amanda W. Lund|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0